For the quarter ending 2025-09-30, IONS had $41,037K increase in cash & cash equivalents over the period. -$136,707K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 156,721 | - |
| Cost of sales | 2,193 | - |
| Drug discovery | 28,412 | - |
| Drug development | 120,828 | - |
| Medical affairs | 8,874 | - |
| Manufacturing and development chemistry | 15,790 | - |
| R&d support | 23,093 | - |
| Selling, general and administrative | 86,565 | - |
| Other segment items | -428 | - |
| Net loss | -128,606 | -23,387 |
| Depreciation | 2,255 | 4,494 |
| Amortization of right-of-use operating lease assets | 1,626 | 5,177 |
| Amortization of other assets | 621 | 1,180 |
| Amortization of discount on investments, net | 5,085 | 12,978 |
| Amortization of debt issuance costs | 1,652 | 3,288 |
| Non-cash royalty revenue related to sale of royalties | 13,584 | 24,894 |
| Non-cash interest related to sale of future royalties | 17,799 | 37,165 |
| Stock-based compensation expense | 31,146 | 59,408 |
| Loss (gain) on investments, net | 29,908 | -20,471 |
| Non-cash losses related to other assets | -3,940 | 297 |
| Contracts receivable | -27,972 | -39,608 |
| Inventories | 2,135 | 12,465 |
| Other current and long-term assets | 100,953 | 22,536 |
| Accounts payable | -8,807 | -20,309 |
| Income taxes | 20 | 47 |
| Accrued compensation | 10,455 | -23,050 |
| Accrued liabilities and other current liabilities | 84,148 | 3,535 |
| Deferred contract revenue | -16,113 | -34,488 |
| Net cash used in operating activities | -131,437 | 563 |
| Purchases of short-term investments | 323,938 | 802,657 |
| Proceeds from sale of short-term investments | 422,206 | 880,545 |
| Purchases of property, plant and equipment | 5,270 | 24,882 |
| Acquisition of licenses and other assets, net | 1,660 | 2,615 |
| Net cash provided by (used in) investing activities | 91,338 | 50,391 |
| Proceeds from issuance of common stock through equity plans, net | 81,259 | 3,528 |
| Proceeds from issuance of common stock in public offering, net | 0 | - |
| Principal payments on mortgage debt | 41 | 82 |
| Net cash provided by financing activities | 81,218 | 3,446 |
| Effects of exchange rates on cash | -82 | 827 |
| Net increase (decrease) in cash and cash equivalents | 41,037 | 55,227 |
| Cash and cash equivalents at beginning of period | 242,077 | - |
| Cash and cash equivalents at end of period | 338,341 | - |
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)